Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 10, 2025 | June 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atara Biotherapeutics, Inc.
Report date June 10, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,368 |
Reported balance
After 2025-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 7,828 · Balance 17,368 F1: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. F2: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
F2: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 12, 2025 20:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 7,828 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002139 · form4.xml · nonDerivative · entry 1 Roncarolo Maria Grazia · CIK 0001811671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,368 F1 · shares: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. F2 · balance_after: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 18:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001058 · form4.xml · nonDerivative · entry 1 Roncarolo Maria Grazia · CIK 0001811671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,500 F1 · shares: These restricted stock units shall vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 19:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 79,500 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001140361-23-028154 · form4.xml · derivative · entry 2 Roncarolo Maria Grazia · CIK 0001811671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2033-05-30 F2 · derivative.exercise_date: The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 19:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-028154 · form4.xml · nonDerivative · entry 1 Roncarolo Maria Grazia · CIK 0001811671 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,500 F1 · shares: These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 16:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001140361-22-024162 · form4.xml · derivative · entry 2 Roncarolo Maria Grazia · CIK 0001811671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2032-06-22 F2 · derivative.exercise_date: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 16:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 20,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-024162 · form4.xml · nonDerivative · entry 1 Roncarolo Maria Grazia · CIK 0001811671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 F1 · shares: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 19:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001140361-21-020439 · form4.xml · derivative · entry 2 Roncarolo Maria Grazia · CIK 0001811671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 19:11 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-020439 · form4.xml · nonDerivative · entry 1 Roncarolo Maria Grazia · CIK 0001811671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 F1 · shares: These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 11, 2020 Filed May 12, 2020 16:08 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 59,500 | $0.00 Strike: $10.25 | $0.00 |
DisclosureSEC source: 0001209191-20-028472 · doc4.xml · derivative · entry 1 Roncarolo Maria Grazia · CIK 0001811671 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,500 Underlying: Common Stock · 59,500 shares Expires 2030-05-10 F1 · derivative.exercise_date: 1/3rd of the shares will vest on the first, second and third anniversaries of the grant date, subject to the Director's Continuous Service (as defined in the Plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.